Completion of Divesture of Non-US Assets

By Finance News On Oct 2, 2024

“The breadth of these data reflects our strategy to advance diverse modalities for difficult-to-treat cancers,” said Jay Bradner , M.D., executive vice president, Research and Development, and chief scientific officer at Amgen. “These ESMO results underscore our leadership in oncology, contributing significant advancements with both investigational and established therapies. Guided by a deep understanding of cancer biology and leveraging incisive therapeutics, we can target dominant drivers of disease with unprecedented precision.”

Key presentations include:

First findings from the Phase 1b study of LUMAKRAS ^® plus Vectibix ^® in combination with FOLFIRI in first-line patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Phase 1 dose escalation and initial dose expansion data from AMG 193 selected for a presidential symposium session.
First-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer (mCRPC).

For more information on the Amgen abstracts, see below.

Abstracts and Presentation Times:

Amgen Sponsored Abstracts

LUMAKRAS ^® (sotorasib) plus Vectibix ^® (panitumumab)

Sotorasib (soto) + panitumumab (pani) and FOLFIRI in the first line (1L) setting for KRAS-G12C mutated metastatic colorectal cancer (mCRC): Safety and efficacy from the phase 1b CodeBreaK 101 study
Abstract #505O, Proffered Paper Oral Session: 2, Madrid Auditorium – Hall 2, Sunday, September 15 from 3: 05 – 3:15 p.m. CEST

AMG 193

Phase 1 dose escalation and initial dose expansion results of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors
Abstract #3482, Proffered Paper Oral Session: Presidential Symposium III: Eyes to the Future, Barcelona Auditorium – Hall 2, Monday, September 16 from 16:30 – 18:15 p.m. CEST

Xaluritamig

C irculating tumor cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Abstract #1610P, Poster, September 15
Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a Phase 1 study
Abstract #1598P, Poster, September 15

LUMAKRAS ^® (sotorasib) for NSCLC

Sotorasib long-term clinical outcomes in pre-treated KRAS G12C-mutated advanced NSCLC: pooled analysis from the CodeBreaK clinical trials
Abstract #1305P, Poster, September 14
Clinical characteristics and therapeutic sequences of KRAS G12C advanced Non-Small Cell Lung Cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)
Abstract #1307P, Poster, September 14

Bemarituzumab

Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Abstract #1420P,…